Edgewood Oncology has raised $20,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Cook played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Edgewood Oncology
Advancing a first-in-class treatment for difficult-to-treat cancers. Edgewood Oncology is a clinical-stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. Our mission is to develop an innovative medicine that improves and extends the lives of patients with the greatest unmet medical needs.

To learn more about Edgewood Oncology, visit http://www.edgewoodoncology.com/

Contact:
David Cook, Chief Executive Officer
508-281-9912
https://www.linkedin.com/in/davidncook/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.